Naklofen (Diclofenac Sodium)

Diclofenac sodium works by inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which are essential for prostaglandin production. Lower prostaglandin levels diminish the inflammatory response and reduce the transmission of pain signals from peripheral tissues to the central nervous system.

The dosage of Naklofen is determined by the prescribing clinician based on the patient’s condition, weight, and response to therapy. Healthcare professionals select the appropriate amount and frequency, and patients should follow the prescription label and medical advice exactly.

Diclofenac sodium is generally contraindicated during pregnancy, especially in the third trimester, and should be used only if the potential benefit outweighs the risk. Breastfeeding mothers should consult a healthcare provider, as the drug can be excreted in milk and may affect the infant.

To order Naklofen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Naklofen (diclofenac sodium) is a potent NSAID with a relatively rapid onset when given intramuscularly, offering stronger analgesia than some oral NSAIDs such as ibuprofen. However, its safety profile regarding gastrointestinal, renal, and cardiovascular risks is similar to other potent NSAIDs, so risk‑benefit assessment remains essential.

Naklofen should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Do not freeze the vials, and keep them out of reach of children. Follow standard aseptic handling procedures when preparing for injection.

Naklofen is supplied as a sterile solution for intramuscular injection. A qualified healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, using aseptic technique. The injection site should be rotated as appropriate, and the patient monitored for any immediate reactions.

Serious risks include gastrointestinal bleeding, ulceration, and perforation; cardiovascular events such as myocardial infarction or stroke; severe liver injury; and acute kidney failure. Patients should be monitored for signs of these complications, especially if they have pre‑existing risk factors.

Naklofen should be avoided in patients with known hypersensitivity to diclofenac or other NSAIDs, those with active gastrointestinal bleeding, severe heart failure, uncontrolled hypertension, advanced renal or hepatic disease, and in the third trimester of pregnancy. Clinicians must evaluate each individual’s medical history before prescribing.